Therefore, subjects with higher baseline PSA levels had higher velocity of PSA decline and shorter time to achieve the nadir level after treatment initiation, which was consistent with higher drug-killing effect on leuprorelin-sensitive cancer cells in these subjects. The gene discussed is KLK3; the disease is cancer.